Approvals, Surges, And Variants
More incremental vaccine news greeted markets Wednesday as AstraZeneca and the University of Oxford’s COVID-19 shot won approval in the UK, marking the first regulatory clearance for the injection. Although Astra's shot presents fewer logistical challenges than the more effective Pfizer-BioNTech vaccine, there are still questions about its efficacy stemming from somewhat confusing trial data. Approval in the US and the EU isn't imminent, although German officials said the process could procee
3 thoughts on “Approvals, Surges, And Variants”
I had read that 20 million vaccines would be administered by year end- last I read we are at 2.1 million.
Yeah the logistics issue alone is a true nightmare especially when so many are out of work or have been avoiding healthcare in general due to exorbitant costs for decades. There is no real functional delivery system capable of managing a two injection immunization across the entire population in a matter of months. I read that once delivered the Pfizer vaccine lasts about 5 days at a hospital in cold storage. The dry ice required for shipping is itself becoming a scarce commodity.
If this UK covid variant is in rural Colorado- I am pretty sure it is everywhere.